Compare Citius Pharmaceuticals Inc (CTXR) vs Rockwell Automation (ROK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Rockwell Automation — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Rockwell Automation trades at $470.5 (market cap $52.27B). The key difference: Rockwell Automation is far larger — about 3570.4× Citius Pharmaceuticals Inc's market cap, and Rockwell Automation pays a 1.18% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | ROK | |
|---|---|---|
Market Cap | $14.64M | $52.27B |
Sector | Health | Industrials |
52-Week High | $1.82 | $495.08 |
52-Week Low | $0.53 | $328.67 |
Enterprise Value | $10.86M | $55.90B |
Dividend Yield | — | 1.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Rockwell Automation (ROK) trades at $460.45, down 2.47% today, with a neutral technical signal and bullish moving averages. The company shows strong profitability with 48.92% gross margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights leadership in industrial automation and AI integration, including new FactoryTalk software launches and WEF recognition for its Singapore facility.
ROK presents a mixed outlook with solid fundamentals but premium valuation (P/E 47.81). Analyst consensus is cautious with 64% hold ratings, though price targets suggest modest upside to $471.71. Key risks include execution challenges in scaling MES integration and industrial sector volatility. The stock offers growth exposure to industrial automation trends with dividend income support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →
